Table 2 The characteristics and outcomes of the patients with and without bone loss
wBL group (N = 23) | w/oBL group (N = 16) | p-value | |
|---|---|---|---|
Characteristics | |||
Female gender | 82.6% | 75% | 0.69 |
Age at the onset of primary disease (years, median [IQR]) | 10.5 [6.8 to 12.9] | 10.9 [9.1 to 13.0] | 0.27 |
Primary disease | |||
SLE | 60.9% | 50.0% | 0.53 |
sJIA | 21.7% | 6.3% | 0.37 |
Others | 17.4% | 43.8% | 0.15 |
Age at the evaluation of osteoporosis (years, median [IQR]) | 11.7 [8.0 to 14.6] | 12.2 [10.9 to 13.7] | 0.42 |
Age at the initiation of glucocorticoid therapy (years, median [IQR]) | 11.0 [7.3 to 14.0] | 11.4 [10.0 to 13.2] | 0.28 |
Body weight at the initiation of glucocorticoid therapy (kg, median [IQR]) | 33.0 [20.4 to 44.2] | 37.1 [29.3 to 42.1] | 0.51 |
Hospitalization during the study period | 100% | 100% | 1.00 |
Length of hospitalization during the study period (days, median [IQR]) | 94 [68 to 110] | 78 [56.5 to 88] | 0.11 |
Length of the period between the initiation of glucocorticoid therapy and evaluation of osteoporosis (years, median [IQR]) | 0.9 [0.7 to 1.2] | 0.8 [0.6 to 1.0] | 0.14 |
Cumulative prednisolone-equivalent dose of glucocorticoids (mg, median [IQR]) | 11,300 [8146 to 15,260] | 12,501 [9216 to 13,777] | 0.83 |
Cumulative prednisolone-equivalent dose of glucocorticoids per body weight per day (mg/kg/day, median [IQR]) | 1.1 [0.8 to 1.5] | 1.2 [0.6 to 1.5] | 0.66 |
Number of mPSLPT (median [IQR]) | 2 [1 to 2] | 2 [2 to 2] | 0.75 |
Cumulative prednisolone-equivalent dose of glucocorticoids except mPSLPT (mg, median [IQR]) | 6222 [4353 to 8973] | 5678 [4764 to 6637] | 0.35 |
Cumulative prednisolone-equivalent dose of glucocorticoids per body weight per day except mPSLPT (mg/kg/day, median [IQR]) | 0.6 [0.5 to 0.8] | 0.6 [0.4 to 0.7] | 0.33 |
Use of immunosuppressive drugsa | 82.6% | 68.8% | 0.44 |
Use of tocilizumab | 8.7% | 0% | 0.50 |
Supplementation of vitamin D | 43.5% | 61.5% | 0.52 |
Supplementation of calcium | 0.0% | 12.5% | 0.16 |
Alendronate therapy | |||
before the evaluation of osteoporosis | 34.7% | 62.5% | 0.11 |
within 3 months after the initiation of glucocorticoid therapy | 13.0% | 56.3% | < 0.01 |
Outcomes | |||
Z-score of L2–4 lumbar BMD (median [IQR]) | −2.74 [−3.62 to −2.29] | −0.61 [−1.51 to 0.18] | < 0.01 |
Fracture history | 30.4% | 0% | 0.03 |
Long bone fracture of the lower extremities | 0% | 0% | 1.00 |
Vertebral compression fracture | 30.4% | 0% | 0.03 |
Two or more long bone fractures of the upper extremities | 0% | 0% | 1.00 |